• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: genetically modified CD34+ hematopoietic stem cells using a lentiviral vector carrying the beta A-T87Q-globin gene
Date Designated: 07/11/2024
Orphan Designation: Treatment of beta-thalassemia
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Kanglin Biotechnology (Hangzhou) Co., Ltd.
Room 301, Building No.4, No.291, Fucheng Road
Hangzhou Economic and Technological Development Zone, Zhejiang Province
China

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-